160 related articles for article (PubMed ID: 23277506)
1. Implementing a pharmacovigilance program to evaluate cutaneous adverse drug reactions in an antiretroviral access program.
Mudzviti T; Sibanda M; Gavi S; Maponga CC; Morse GD
J Infect Dev Ctries; 2012 Nov; 6(11):806-8. PubMed ID: 23277506
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous adverse drug reactions among people living with human immunodeficiency virus in a tertiary care hospital in Johor, Malaysia.
Chua KY; Tey KE
Int J STD AIDS; 2022 Aug; 33(9):812-820. PubMed ID: 35775121
[TBL] [Abstract][Full Text] [Related]
3. Identification of discrepancies between adverse drug reactions coded by medical records technicians and those reported by the pharmacovigilance team in pediatrics: An intervention to improve identification, reporting, and coding.
Soyer J; Necsoiu D; Desjardins I; Lebel D; Bussières JF
Arch Pediatr; 2019 Oct; 26(7):400-406. PubMed ID: 31611146
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Cutaneous Adverse Drug Reactions (ADR) Reported at an ADR Monitoring Center of a Tertiary Care Teaching Institute in Central India.
Chindhalore CA; Gupta AV; Dakhale GN; Srivastava A
Cureus; 2024 Feb; 16(2):e53706. PubMed ID: 38455795
[TBL] [Abstract][Full Text] [Related]
5. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
[TBL] [Abstract][Full Text] [Related]
6. Common causes and characteristics of adverse drug reactions in older adults: a retrospective study.
Woo SD; Yoon J; Doo GE; Park Y; Lee Y; Lee SH; Lee YH; Ye YM
BMC Pharmacol Toxicol; 2020 Dec; 21(1):87. PubMed ID: 33303036
[TBL] [Abstract][Full Text] [Related]
7. An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme.
Masuka JT; Khoza S
Pharmacol Res Perspect; 2020 Oct; 8(5):e00657. PubMed ID: 32930524
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous adverse drug reactions notified by pharmacovigilance in a tertiary care hospital in north India.
Mittal N; Gupta M; Singla M
Cutan Ocul Toxicol; 2014 Dec; 33(4):289-93. PubMed ID: 24517496
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Reporting Adverse Drug Reactions in Paediatric Patients in a University Hospital in the Netherlands.
Dittrich ATM; Draaisma JMT; van Puijenbroek EP; Loo DMWMT
Paediatr Drugs; 2020 Aug; 22(4):425-432. PubMed ID: 32557243
[TBL] [Abstract][Full Text] [Related]
10. Causality assessment of adverse drug reaction reports using an expert-defined Bayesian network.
Rodrigues PP; Ferreira-Santos D; Silva A; Polónia J; Ribeiro-Vaz I
Artif Intell Med; 2018 Sep; 91():12-22. PubMed ID: 30077492
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
12. Adverse drug reactions of analgesic medicines: analysis of the Romanian pharmacovigilance database.
Cazacu I; Stroe R; Dondera R; Mogosan C; Haramburu F; Fourrier-Réglat A; Loghin F
Fundam Clin Pharmacol; 2018 Jun; 32(3):330-336. PubMed ID: 29314262
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous Adverse Drug Reaction Monitoring in a Tertiary Care Centre.
Kaur K; Kanwal P; Goyal P; Singh P; Yakhmi S; Jain S; Kaushal S
Curr Drug Saf; 2020; 15(3):215-221. PubMed ID: 32735525
[TBL] [Abstract][Full Text] [Related]
14. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
[TBL] [Abstract][Full Text] [Related]
15. Nevirapine: Most Common Cause of Cutaneous Adverse Drug Reactions in an Outpatient Department of a Tertiary Care Hospital.
Pawar MP; Pore SM; Pradhan SN; Burute SR; Bhoi UY; Ramanand SJ
J Clin Diagn Res; 2015 Nov; 9(11):FC17-20. PubMed ID: 26672558
[TBL] [Abstract][Full Text] [Related]
16. CD4 count and risk of anti-tuberculosis drug-associated cutaneous reactions in HIV-infected Thai patients.
Boonyagars L; Hirunwiwatkul P; Hurst CP
Int J Tuberc Lung Dis; 2017 Mar; 21(3):338-344. PubMed ID: 28225346
[TBL] [Abstract][Full Text] [Related]
17. HAART induced adverse drug reactions: a retrospective analysis at a tertiary referral health care center in India.
Anwikar SR; Bandekar MS; Smrati B; Pazare AP; Tatke PA; Kshirsagar NA
Int J Risk Saf Med; 2011; 23(3):163-9. PubMed ID: 22020396
[TBL] [Abstract][Full Text] [Related]
18. Pharmacovigilance in China: development and challenges.
Zhao Y; Wang T; Li G; Sun S
Int J Clin Pharm; 2018 Aug; 40(4):823-831. PubMed ID: 30051225
[TBL] [Abstract][Full Text] [Related]
19. [Use of Nadis(®) software to improve adverse drug reaction reporting of antiretroviral drugs: experience in south west of France (midi-pyrénées)].
Pochard L; Hauviller L; Cuzin L; Eyvrard F; Sommet A; Montastruc JL; Bagheri H
Therapie; 2014; 69(2):149-55. PubMed ID: 24926633
[TBL] [Abstract][Full Text] [Related]
20. Adverse drug reactions reported to a provincial public health sector pharmacovigilance programme in South Africa.
Jones J; Swart A; Tommy E; Cohen K; Stewart A; Voget J; Blockman M
S Afr Med J; 2020 Nov; 110(12):1226-1230. PubMed ID: 33403970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
